Nothing Special   »   [go: up one dir, main page]

BRPI0713743C1 - composto, e, composição farmacêutica - Google Patents

composto, e, composição farmacêutica

Info

Publication number
BRPI0713743C1
BRPI0713743C1 BRPI0713743A BRPI0713743A BRPI0713743C1 BR PI0713743 C1 BRPI0713743 C1 BR PI0713743C1 BR PI0713743 A BRPI0713743 A BR PI0713743A BR PI0713743 A BRPI0713743 A BR PI0713743A BR PI0713743 C1 BRPI0713743 C1 BR PI0713743C1
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
salt
melatonin
prodrug
Prior art date
Application number
BRPI0713743A
Other languages
English (en)
Inventor
Uchikawa Osamu
Takai Takafumi
Koike Tatsuki
Hoashi Yasutaka
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BRPI0713743A2 publication Critical patent/BRPI0713743A2/pt
Publication of BRPI0713743B1 publication Critical patent/BRPI0713743B1/pt
Publication of BRPI0713743B8 publication Critical patent/BRPI0713743B8/pt
Publication of BRPI0713743C1 publication Critical patent/BRPI0713743C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

composto ou um sal do mesmo, pró-droga, e, composição farmacêutica. a presente invenção fornece um composto representado pela fórmula que é útil como um agente para a profilaxia ou tratamento de doença relacionadas com a ação de melatonina ou um sal do mesmo e outros.
BRPI0713743A 2006-06-19 2007-06-18 composto, e, composição farmacêutica BRPI0713743C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006168518 2006-06-19
JP2006-168518 2006-06-19
PCT/JP2007/062645 WO2007148808A1 (en) 2006-06-19 2007-06-18 Tricyclic compound and pharmaceutical use thereof

Publications (4)

Publication Number Publication Date
BRPI0713743A2 BRPI0713743A2 (pt) 2012-11-06
BRPI0713743B1 BRPI0713743B1 (pt) 2020-03-17
BRPI0713743B8 BRPI0713743B8 (pt) 2020-05-19
BRPI0713743C1 true BRPI0713743C1 (pt) 2021-05-25

Family

ID=38519675

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713743A BRPI0713743C1 (pt) 2006-06-19 2007-06-18 composto, e, composição farmacêutica

Country Status (36)

Country Link
US (5) US8030337B2 (pt)
EP (1) EP2029561B1 (pt)
JP (1) JP5222737B2 (pt)
KR (1) KR101442274B1 (pt)
CN (1) CN101506181B (pt)
AR (1) AR061478A1 (pt)
AU (1) AU2007261953B2 (pt)
BR (1) BRPI0713743C1 (pt)
CA (1) CA2655753C (pt)
CL (1) CL2007001779A1 (pt)
CO (1) CO6150175A2 (pt)
CR (1) CR10524A (pt)
CY (1) CY1115729T1 (pt)
DK (1) DK2029561T3 (pt)
ES (1) ES2523410T3 (pt)
GE (1) GEP20125392B (pt)
HK (1) HK1130049A1 (pt)
HR (1) HRP20141046T1 (pt)
IL (1) IL195639A0 (pt)
JO (1) JO2999B1 (pt)
MA (1) MA30523B1 (pt)
ME (2) ME01998B (pt)
MX (1) MX2008015842A (pt)
MY (1) MY158069A (pt)
NO (1) NO341739B1 (pt)
NZ (1) NZ574037A (pt)
PE (1) PE20080941A1 (pt)
PL (1) PL2029561T3 (pt)
PT (1) PT2029561E (pt)
RS (1) RS53616B1 (pt)
RU (1) RU2456278C2 (pt)
SI (1) SI2029561T1 (pt)
TW (1) TWI402261B (pt)
UA (1) UA99104C2 (pt)
WO (1) WO2007148808A1 (pt)
ZA (1) ZA200900151B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
CA2674045A1 (en) * 2006-12-28 2008-07-17 Takeda Pharmaceutical Company Limited Tricyclic compound and pharmaceutical use thereof
CN103450111B (zh) * 2013-09-04 2015-07-08 温州大学 一种苯并噻唑杂环化合物的绿色合成方法
US20160253891A1 (en) * 2015-02-27 2016-09-01 Elwha Llc Device that determines that a subject may contact a sensed object and that warns of the potential contact
AU2017205722B2 (en) * 2016-01-08 2022-02-17 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for autism spectrum disorder
EP3400940B1 (en) 2016-01-08 2024-08-07 Takeda Pharmaceutical Company Limited Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium
MX2019004610A (es) 2016-10-19 2019-09-18 Monsanto Technology Llc Composiciones y métodos para alterar la floración y arquitectura de planta para mejorar el potencial de rendimiento.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292226C (en) * 1986-01-16 1991-11-19 Terumi Hachiya Indenothiazole derivative and process for preparing the same
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US6180657B1 (en) * 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
FR2725985B1 (fr) * 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19502895A1 (de) 1995-01-31 1996-08-01 Merck Patent Gmbh 4-Mercapto-benzoylguanidin-Derivate
CA2176854A1 (en) 1995-06-07 1996-12-08 Daniel J. Keavy N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
US5753709A (en) * 1995-06-07 1998-05-19 Bristol-Myers Squibb Company N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
US5596019A (en) * 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
FR2742153B1 (fr) * 1995-12-12 1998-02-13 Innothera Lab Sa Utilisation de derives tricycliques du 1,4-dihydro-1,4- dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique
PT885210E (pt) * 1996-03-08 2002-09-30 Takeda Chemical Industries Ltd Compostos triciclicos que possuem afinidade de ligacao para receptores de melatonina sua producao e utilizacao
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
SE9802360D0 (sv) * 1998-07-01 1998-07-01 Wikstroem Hakan Vilhelm New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins ((basic)-N-substituted and (basic)-N,N-disubstituted derivatives of 2,6-diamino-thiazolo(4,5-f)indan and 2,7-di-amino-thiazolo(4,5-g)tetralin
AU6595100A (en) * 1999-08-20 2001-03-19 Takeda Chemical Industries Ltd. Percutaneous absorption agents
EP2305219A1 (en) * 2000-11-17 2011-04-06 Takeda Pharmaceutical Company Limited Pharmaceutical preparations coated with a copolyvidone-containing coating
JP3633895B2 (ja) 2000-11-17 2005-03-30 武田薬品工業株式会社 コポリビドン含有製剤
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
US20060223877A1 (en) 2005-03-31 2006-10-05 Zemlan Frank P Methods of treatment utilizing certain melatonin derivatives
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica

Also Published As

Publication number Publication date
CL2007001779A1 (es) 2008-01-04
US20110196003A1 (en) 2011-08-11
RU2456278C2 (ru) 2012-07-20
EP2029561A1 (en) 2009-03-04
SI2029561T1 (sl) 2014-11-28
NO341739B1 (no) 2018-01-15
TW200815376A (en) 2008-04-01
AU2007261953B2 (en) 2012-11-08
CN101506181A (zh) 2009-08-12
WO2007148808A1 (en) 2007-12-27
ZA200900151B (en) 2010-03-31
CA2655753A1 (en) 2007-12-27
GEP20125392B (en) 2012-02-10
HK1130049A1 (en) 2009-12-18
EP2029561B1 (en) 2014-08-13
TWI402261B (zh) 2013-07-21
US20110190361A1 (en) 2011-08-04
ES2523410T3 (es) 2014-11-25
BRPI0713743A2 (pt) 2012-11-06
AU2007261953A1 (en) 2007-12-27
US8895591B2 (en) 2014-11-25
DK2029561T3 (da) 2014-11-10
CY1115729T1 (el) 2017-01-25
CR10524A (es) 2009-01-27
JP5222737B2 (ja) 2013-06-26
MY158069A (en) 2016-08-30
IL195639A0 (en) 2009-09-01
JP2009541202A (ja) 2009-11-26
AR061478A1 (es) 2008-08-27
RU2009101299A (ru) 2010-07-27
MX2008015842A (es) 2009-01-09
PL2029561T3 (pl) 2015-03-31
CO6150175A2 (es) 2010-04-20
US20130079374A1 (en) 2013-03-28
KR20090023701A (ko) 2009-03-05
US8236837B2 (en) 2012-08-07
US20090182023A1 (en) 2009-07-16
US8552037B2 (en) 2013-10-08
ME00582A (en) 2011-12-20
RS53616B1 (en) 2015-04-30
BRPI0713743B1 (pt) 2020-03-17
HRP20141046T1 (hr) 2014-12-19
PE20080941A1 (es) 2008-09-04
NZ574037A (en) 2011-10-28
CN101506181B (zh) 2011-12-07
US8030337B2 (en) 2011-10-04
US8349879B2 (en) 2013-01-08
CA2655753C (en) 2015-08-04
MA30523B1 (fr) 2009-06-01
PT2029561E (pt) 2014-11-12
US20140011849A1 (en) 2014-01-09
UA99104C2 (uk) 2012-07-25
JO2999B1 (ar) 2016-09-05
BRPI0713743B8 (pt) 2020-05-19
ME01998B (me) 2015-05-20
KR101442274B1 (ko) 2014-09-22
NO20090234L (no) 2009-02-12

Similar Documents

Publication Publication Date Title
BR112012032087A2 (pt) composto, medicamento, e, uso de um composto
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
BR112015020650A2 (pt) inibidores de histona demetilases
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
UY32730A (es) Inhibidores de cyp17
CR10250A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
BRPI0720993B8 (pt) usos de compostos análogos de ciclopamina
CR20110016A (es) Compuestos quimicos 251
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112014025711A8 (pt) composto, medicamento, e, uso de um composto
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
ECSP099552A (es) Compuestos triciclicos, composiciones y procedimientos
CR10479A (es) Modulares bencimidazolicos de vr1
BRPI0713743C1 (pt) composto, e, composição farmacêutica
BRPI1014802B8 (pt) profármacos de triptolida.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
BR112012024822B8 (pt) Composto, uso de um composto e composição farmacêutica
BR112012004851B8 (pt) uso de um derivado de tiazol
BRPI0921097B8 (pt) composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
BR112012027387A2 (pt) composição para controle de doenças de plantas e uso da mesma
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112014026198A2 (pt) compostos pirazol como inibidores de sglt1
BR112012024586A2 (pt) compostos de purina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE UM PARECER DE DEFERIMENTO NOTIFICADO NA RPI NO 2560 DE28/01/2020, TENDO SIDO CONSTATADO QUE ESTA NOTIFICACAO FOI EFETUADA COM INCORRECOES (A PETICAOCORRETA QUE CONTEM A FOLHA 1 RD, QUADRO REIVINDICATORIO REFORMULADO E RESUMO E RJ NO870200002820 DE 07/01/2020).

B16D Grant of patent or certificate of addition of invention cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 16.1 NA RPI NO 2567 DE 17/03/2020 POR TER SIDO INDEVIDA.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2573 DE 28/04/2020 QUANTO AO TITULO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed